Used as a key intermediate in the synthesis of pharmaceutical peptides, particularly in the development of protease inhibitors. Its structure supports selective binding and enhanced stability in drug candidates targeting viral enzymes, such as those in hepatitis C and HIV therapies. Commonly employed in solid-phase peptide synthesis due to the fluorenylmethoxycarbonyl (Fmoc) protecting group, allowing for mild deprotection conditions and high yields in multi-step reactions. Also utilized in research for designing enzyme inhibitors with improved bioavailability and target specificity.